ProMISe: results of septic shock trial published

ProMISe was a multi-centre, randomised controlled trial of the clinical and cost-effectiveness of early, goal-directed, protocolised resuscitation for emerging septic shock.

The trial was open in over 50 UK hospital sites and closed to recruitment in July 2014. It was an important, collaborative, NIHR-funded research effort between emergency, acute and critical care medicine.

We would like to congratulate Central Manchester University Hospitals NHS Foundation Trust’s Emergency Department and Salford Royal NHS Foundation Trust’s Critical Care research teams, who were among the top recruiters to the study nationally.

The study results suggests that early goal directed therapy in septic shock patients did not improve outcome. This result is similar to other recent trials in North America and Australasia, contradicting the findings of the single centre study which has driven practice since 2001.

The results of the clinical and cost-effectiveness evaluation of ProMISe were presented on Tuesday 17 March at the opening session of the International Symposium on Intensive Care and Emergency Medicine Annual Congress in Brussels.

The findings have been published on the New England Journal of Medicine website.

Find out more on the ProMISe trial site.

The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the HTA programme, NIHR, NHS, the Department of Health or the Sponsor (ICNARC).